Progesterone, progestins, and the heart

Reviews in Cardiovascular Medicine

Volumn 11, Issue 4, 2010, Pages 228-236

  Bernstein, Paula ^a   Pohost, Gerald ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarkers; Coronary heart disease; Myocardial infarction; Progesterone; Progestin

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL ACETATE; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL PLUS NORGESTIMATE; ESTRADIOL PLUS PROGESTERONE PLUS TESTOSTERONE; ESTRADIOL PROPIONATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; THROMBOXANE A2 RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG DERIVATIVE;

BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY SPASM; GLUCOSE BLOOD LEVEL; HEART; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LIPID METABOLISM; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASOCONSTRICTION; VASODILATATION; VASOSPASM; CHEMICALLY INDUCED DISORDER; CORONARY BLOOD VESSEL; DRUG EFFECT; ESTROGEN THERAPY; HEART INFARCTION; HEART MUSCLE; METABOLISM; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; STROKE; WOMEN'S HEALTH;

CORONARY VESSELS; ESTROGEN REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE; MYOCARDIAL INFARCTION; MYOCARDIUM; NORETHINDRONE; PATIENT SELECTION; PROGESTERONE; PROGESTINS; RISK ASSESSMENT; RISK FACTORS; STROKE; WOMEN'S HEALTH;

EID: 79954433482     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0557     Document Type: Review

References (28)

1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
2. Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril. 2000;73:516-521. (Pubitemid 30109647)
3. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001;75:898-915.
4. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286:R233-R249. (Pubitemid 38140366)
5. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999;19:1034-1040. (Pubitemid 29177353)
6. English KM, Jones RD, Jones TH, et al. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res. 2001;33:645-652. (Pubitemid 33151462)
7. Jiang CW, Sarrel PM, Lindsay DC, et al. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol. 1992;211:163-167.
8. Minshall RD, Pavenik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol. 2002;92:701-708. (Pubitemid 34671040)
9. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327. (Pubitemid 27112931)
10. 2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol. 2001;281:H1498-H1507.
11. Hermsmeyer RK, Mishra RG, Pavcnik D, et al. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol. 2004;24:955-961. (Pubitemid 38620878)
12. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36:2154-2159.
13. Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol. 2004;124:802-808. (Pubitemid 38365786)
14. Borgfeldt C, Li C, Samsloe G. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhlbitor-1. Climacteric. 2004;7:78-85. (Pubitemid 38367166)
15. Perera M, Sattar N, Petrie JR, et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1140-1143. (Pubitemid 32322994)
16. Kernohan AFB, Sattart N, Hilditch T, et al. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol (Oxf). 2007;66:27-34. (Pubitemid 44952491)
17. McKenzie J, Jaap AJ, Gallacher S, et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf). 2003;59:682-689.
18. Pedersen SH, Pedersen NG, Dalsgaard T, et al. Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand white rabbit. Climacteric. 2004;7:12-22. (Pubitemid 38367159)
19. Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol. 2003;188:1132-1140. (Pubitemid 36589081)
20. Sherwood A, Bower JK, McFetridge-Durdle J, et al. Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in post-menopausal women. Arterioscler Thromb Vasc Biol. 2007;27:1782-1787.
21. Perera M, Petrie JR, Hillier C, et al. Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Hum Reprod. 2002;17:497-502. (Pubitemid 34168466)
22. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med. 2008;168:2245-2253.
23. Bray PF, Larson JC, LaCroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol. 2008;101:1599-1605.
24. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12-23.
25. Harman SB, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3-12. (Pubitemid 40675116)
26. Hodis HN. ELITE: Early versus Late Intervention Trial with Estradiol. Study NCT00114517. http://www.clinicaltrials.gov/show/NCT00114517. Accessed September 17, 2010.
27. Toh S, Hernández-Díaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152:211-217.
28. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:242-255.